IGC Acquires Exclusive Rights for a Potential Alzheimer’s Drug Development Candidate
June 21 2022 - 12:15AM
Business Wire
India Globalization Capital, Inc. (NYSE: IGC) is excited to
announce that one of its subsidiaries reached an Intellectual
Property (IP) license agreement for a potential Alzheimer’s drug
development candidate.
Researchers at the Jawaharlal Nehru Centre for Advanced
Scientific Research (“JNCASR”), in India, conducted about 10 years
of research and discovery work on NMI (Naphthalene Monoimide)
compounds and the role of NMI compounds on neurotoxicity associated
with Alzheimer’s. Neurotoxicity, which can result from exposure to
natural or synthetic substances, causes damage to the brain and the
nervous system. In Alzheimer’s patients, neurotoxicity is linked to
beta amyloid (Aβ) plaques and Neuro Fibrillary Tangles (NFT).
JNCASR’s research based on Alzheimer’s cell lines, identified
one lead NMI molecule, TGR 63, with the potential to reduce beta
amyloid (Aβ) plaques. Further, they demonstrated that the molecule
reduces cognitive decline in a transgenic mouse model of
Alzheimer’s. Their results were published in Advanced Therapeutics
under the title “Naphthalene Monoimide Derivative Ameliorates
Amyloid Burden and Cognitive Decline in a Transgenic Mouse Model of
Alzheimer’s Disease” on January 28, 2021.
IGC acquired exclusive global rights to the molecule and plans
to develop this NMI lead candidate further. IGC is currently in
human trials with IGC-AD1 that targets neuropsychiatric symptoms
associated with dementia in Alzheimer’s. It is currently being
evaluated as an Alzheimer’s symptom modifying agent. TGR-63, the
new molecule, strategically, gives the Company a potential disease
modifying agent and positions the Company to develop a drug that
can potentially treat or modify Alzheimer’s by targeting beta
amyloid (Aβ) plaques.
According to the World Health Organization (2020), worldwide,
about 55 million individuals suffer from dementia, and about 60-70%
of dementia is related to Alzheimer’s. This number is projected to
increase to about 78 million individuals in 2030, with the
estimated total global societal cost of dementia expected to
surpass $2.8 trillion by 2030.
About JNCASR:
Jawaharlal Nehru Centre for Advanced Scientific Research,
located in Bengaluru, India, is an autonomous institution under the
Department of Science and Technology, Government of India.
https://www.jncasr.ac.in/home
About IGC:
IGC has two segments: Infrastructure and Life Sciences. The
company is based in Maryland, U.S.A.
Forward-looking Statements:
This press release contains forward-looking statements. These
forward-looking statements are based largely on IGC’s expectations
and are subject to several risks and uncertainties, certain of
which are beyond IGC’s control. Actual results could differ
materially from these forward-looking statements as a result of,
among other factors, the Company’s failure or inability to
commercialize one or more of the Company’s products or
technologies, including the product or formulation described in
this release, or failure to obtain regulatory approval for the
product or formulation, where required; general economic conditions
that are less favorable than expected, including as a result of the
ongoing COVID-19 pandemic; the FDA’s general position regarding
cannabis- and hemp-based products; and other factors, many of which
are discussed in IGC’s SEC filings. IGC incorporates by reference
the human trial disclosures and Risk Factors identified in its
Annual Reports on Form 10-K filed with the SEC on June 14, 2021,
and Quarterly Reports on Form 10-Q, filed with the SEC on August
11, 2021, and October 29, 2021, as if fully incorporated and
restated herein. In light of these risks and uncertainties, there
can be no assurance that the forward-looking information contained
in this release will occur.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220620005637/en/
Claudia Grimaldi 301-983-0998
IGC Pharma (AMEX:IGC)
Historical Stock Chart
From Aug 2024 to Sep 2024
IGC Pharma (AMEX:IGC)
Historical Stock Chart
From Sep 2023 to Sep 2024